Johnson & Johnson and it subsidiary Janssen Pharmaceuticals were pleased to hear the results of the Jan. 28 ruling that overturned the large judgment against them based on allegations that they violated Louisiana’s Medical Assistance Programs Integrity Law (MAPIL) by misrepresenting the potential risks and side effects of the anti-psychotic drug Risperdal through off-label statements….

This content is for Paid Members only.
Login Register